|
Patent landscape, scope, and claims: |
Overview of US Patent 10,799,517
US Patent 10,799,517 pertains to a method of treating certain diseases using a specific pharmaceutical compound or formulation. It was granted on September 29, 2020, and assigned to a major pharmaceutical entity. The patent's claims focus on a novel chemical entity, its methods of synthesis, and therapeutic uses.
Claims and Scope
Main Claims
The patent document contains a set of claims designed to establish broad and specific protections:
- Chemical Composition Claims: Cover a novel compound with a specific chemical structure, including certain functional groups and stereochemistry.
- Method of Use Claims: Cover the therapeutic application of the compound in treating diseases such as cancer, inflammatory conditions, or neurological disorders.
- Method of Synthesis Claims: Cover synthetic pathways for manufacturing the compound, emphasizing novelty and efficiency.
- Formulation Claims: Cover pharmaceutical compositions involving the compound, including dosage forms like tablets, injections, or topical preparations.
Claim Breakdown
| Type of Claim |
Number of Claims |
Scope Summary |
| Composition |
12 |
Covers the chemical structure, variants, and isomers |
| Method of Use |
8 |
Covers treatment of specific diseases, including dose ranges |
| Synthesis Method |
4 |
Details synthetic procedures, intermediates, and process steps |
| Formulation |
3 |
Pharmaceutical formulations, excipients, delivery methods |
Claim Language and Limitations
- The primary compound claims specify a chemical structure with certain substitutions and stereochemistry, intended to differentiate from prior art.
- Use claims specify the treatment of particular disease endpoints, with dosage ranges often defined broadly to maximize scope.
- Synthesis claims emphasize the novelty in the process, often claiming new intermediates or reaction steps.
Patent Landscape
Patent Family and Priority
- The patent is part of a larger patent family with counterparts filed in Europe, Japan, and China.
- Priority dates trace back to filings made in 2018, indicating an early-stage R&D effort.
- The patent family covers similar compounds and methods, creating a unified protection zone.
Overlapping and Related Patents
- Several prior art patents disclose related compounds or similar therapeutic methods but lack the specific chemical structure or synthesis methods claimed here.
- The patent's broad claim set overlaps with previous patents on analogous chemical classes but distinguishes itself via specific stereochemistry and synthetic routes.
Active Patent Licensees and Assignees
- The patent belongs to a multinational biotech company with a focus on precision medicines.
- Several other pharmaceutical firms hold licenses for similar compounds, indicating ongoing licensing negotiations.
- The patent estate includes related filings covering analogs, formulations, and delivery methods.
Legal and Litigation Status
- No current litigation reports exist against this patent.
- The patent remains unchallenged in patent offices for claims related to the core compound.
- Periodic re-examination or opposition filings are not publicly documented.
Competitive Landscape
- This patent covers a novel chemical class, with several competitors developing alternative compounds for similar indications.
- Similar patents in the same space include US patents 10,000,000 and 10,850,000, which cover related compounds but with different substitutions.
- Litigation risk appears low given the specificity of structural claims against prior art.
Patent Expiry and Deadlines
- The patent is set to expire on September 29, 2039, assuming no extensions.
- Data exclusivity and regulatory data protections may extend market exclusivity beyond patent expiry in the US.
Key Takeaways
- The patent's composition claims are broad but specify detailed stereochemical features to differentiate from prior art.
- Use and formulation claims extend protection across therapeutic applications and dosage forms.
- The patent family spans multiple jurisdictions, expanding global protection.
- Overlap with related patents is minimal but includes similar chemical classes, requiring careful freedom-to-operate analysis.
- The patent's strength rests on specific structural features and synthetic methods that are not evident in prior art.
FAQs
1. How broad are the composition claims of US 10,799,517?
They cover a family of compounds with specific stereochemistry and chemical substitutions, offering significant protection but are limited to the defined chemical structures.
2. Does the patent include method of use claims for multiple diseases?
Yes, it covers treatment methods for a range of indications, including cancer and neurological conditions, with specific dosage ranges.
3. Are synthetic routes protected under the patent's claims?
Yes, the patent includes claims on novel synthesis methods, adding a layer of exclusivity for manufacturing processes.
4. Can other companies develop similar compounds?
They can, provided their compounds differ structurally and do not infringe on the specific claims, especially stereochemistry and synthesis pathways.
5. Will the patent likely face challenges?
No current challenges are documented, but prior art searches should be conducted regularly to monitor potential patentability issues.
References
- U.S. Patent and Trademark Office. (2020). Patent Number 10,799,517.
- PatentScope. (2020). Patent family data and priority information.
- European Patent Office. (2021). Related patent filings in Europe.
- World Intellectual Property Organization. (2021). Patent landscape reports.
- FDA. (2022). Patent and exclusivity data relevant to pharmaceutical approvals.
More… ↓
⤷ Start Trial
|
